# HRT & TRT: Protocols, Evidence Reversal, and the DACH Reality

HRT for women and TRT for men are evidence-based symptom treatments, not longevity drugs. The 2002 WHI scare got over-extrapolated. It enrolled women at a mean age of 63, yet its 18-year follow-up (2017) showed neutral all-cause mortality (HR 0.99), and TRAVERSE (2023) found TRT non-inferior to placebo for major cardiac events in confirmed hypogonadism. The strongest indications stay narrow: vasomotor symptoms for women, plus symptoms and consistently low morning testosterone for men.

In 2002, the Women's Health Initiative torpedoed how doctors prescribed hormones. The 2017 Manson re-analysis and the 2023 TRAVERSE trial quietly took it back. Here is the honest 2026 read for women weighing HRT and men weighing TRT in Germany, Austria, and Switzerland.

## On this page

- Why Did Doctors Stop Prescribing HRT After 2002?
- Does It Matter When You Start HRT?
- What Does HRT Actually Do (and Not Do)?
- Micronized Progesterone or Synthetic Progestin?
- Patch or Pill: Does the Route Change the Risk?
- Should Women Take Testosterone?
- When Is TRT in Men Actually Justified?
- What Did TRAVERSE 2023 Settle About TRT and the Heart?
- Why Crashing Estradiol on TRT Is a Bad Idea
- Is HRT or TRT a Longevity Drug?
- What Does the Krankenkasse Pay For in DACH?
- What Risks Should You Not Gloss Over?

## FAQ

- Ist HRT in den Wechseljahren sicher?
- Östrogen-Pflaster oder Tablette: was ist der Unterschied?
- Was unterscheidet bioidentisches Progesteron von synthetischem Gestagen?
- Ab welchem Testosteronwert ist eine TRT indiziert?
- TRT und Herzinfarkt: was sagt TRAVERSE 2023?
- Was kostet TRT in Deutschland?
- Bekomme ich HRT/TRT über die Krankenkasse?
- Macht TRT unfruchtbar?
- Brauchen Frauen Testosteron?
- Welche Privatkliniken bieten HRT/TRT in DACH an, und worauf muss ich achten?

## Sources

- Rossouw JE, Anderson GL, Prentice RL, et al. (Writing Group for the Women's Health Initiative Investigators). (2002). Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA. https://doi.org/10.1001/jama.288.3.321
- Anderson GL, Limacher M, Assaf AR, et al.. (2004). Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial. JAMA. https://doi.org/10.1001/jama.291.14.1701
- Hersh AL, Stefanick ML, Stafford RS. (2004). National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. https://doi.org/10.1001/jama.291.1.47
- Manson JE, Chlebowski RT, Stefanick ML, et al.. (2013). Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials. JAMA. https://doi.org/10.1001/jama.2013.278040
- Manson JE, Aragaki AK, Rossouw JE, et al.. (2017). Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. https://doi.org/10.1001/jama.2017.11217
- Salpeter SR, Walsh JM, Greyber E, Salpeter EE. (2004). Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. Journal of General Internal Medicine. https://doi.org/10.1111/j.1525-1497.2004.30281.x
- Beral V (Million Women Study Collaborators). (2003). Breast cancer and hormone-replacement therapy in the Million Women Study. The Lancet. https://doi.org/10.1016/S0140-6736(03)14065-2
- Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-Chapelon F. (2008). Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. Journal of Clinical Oncology. https://doi.org/10.1200/JCO.2007.13.4338
- Stute P, Wildt L, Neulen J. (2018). The impact of micronized progesterone on breast cancer risk: a systematic review. Climacteric. https://doi.org/10.1080/13697137.2017.1421925
- Mohammed K, Abu Dabrh AM, Benkhadra K, et al.. (2015). Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2015-2237
- Hodis HN, Mack WJ, Henderson VW, et al. (ELITE Research Group). (2016). Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1505241
- Harman SM, Black DM, Naftolin F, et al.. (2014). Arterial Imaging Outcomes and Cardiovascular Risk Factors in Recently Menopausal Women: A Randomized Trial (KEEPS). Annals of Internal Medicine. https://doi.org/10.7326/M14-0353
- Gleason CE, Dowling NM, Wharton W, et al.. (2015). Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS-Cognitive and Affective Study. PLoS Medicine. https://doi.org/10.1371/journal.pmed.1001833
- The North American Menopause Society (The Menopause Society). (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. https://doi.org/10.1097/GME.0000000000002028
- International Menopause Society. (2024). Menopause and MHT in 2024: addressing the key controversies — an IMS White Paper. IMS
- Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. (2017). AACE/ACE Position Statement on Menopause — 2017 Update. Endocrine Practice. https://doi.org/10.4158/EP171828.PS
- Schaudig K, Stute P, et al. (DGGG, DGE, OEGGG, SGGG). (2020). S3-Leitlinie 'Peri- und Postmenopause — Diagnostik und Interventionen' (AWMF 015/062) — formal validity expired 31 Dec 2024; currently in re-review at AWMF. AWMF / PMC8216766
- Davis SR, Wahlin-Jacobsen S. (2015). Testosterone in women — the clinical significance. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/S2213-8587(15)00284-3
- Davis SR, Baber R, Panay N, et al.. (2019). Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2019-01603
- Snyder PJ, Bhasin S, Cunningham GR, et al. (Testosterone Trials Investigators). (2016). Effects of Testosterone Treatment in Older Men (the T-Trials). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1506119
- Bhasin S, Brito JP, Cunningham GR, et al.. (2018). Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2018-00229
- Mulhall JP, Trost LW, Brannigan RE, et al.. (2018). Evaluation and Management of Testosterone Deficiency: AUA Guideline. Journal of Urology. https://doi.org/10.1016/j.juro.2018.03.115
- Travison TG, Vesper HW, Orwoll E, et al.. (2017). Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2016-2935
- Wu FC, Tajar A, Beynon JM, et al. (European Male Aging Study Group). (2010). Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men (EMAS). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa0911101
- Lincoff AM, Bhasin S, Flevaris P, et al. (TRAVERSE Study Investigators). (2023). Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2215025
- Vigen R, O'Donnell CI, Barón AE, et al.. (2013). Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels. JAMA. https://doi.org/10.1001/jama.2013.280386
- Finkle WD, Greenland S, Ridgeway GK, et al.. (2014). Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men. PLoS One. https://doi.org/10.1371/journal.pone.0085805
- Finkelstein JS, Lee H, Burnett-Bowie SA, et al.. (2013). Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1206168
- Yeap BB, Marriott RJ, Dwivedi G, et al.. (2024). Endogenous Testosterone, Sex Hormone-Binding Globulin, and Risk of Mortality and Cardiovascular Disease in Community-Dwelling Men: An Individual Participant Data Meta-Analysis. Annals of Internal Medicine. https://doi.org/10.7326/M23-2781
- Saigal CS, Gore JL, Krupski TL, et al.. (2007). Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer
- National Academies of Sciences, Engineering, and Medicine. (2020). The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use. National Academies Press, Washington DC
- EMA Pharmacovigilance Risk Assessment Committee (PRAC). (2020). PRAC Recommendation on menopausal hormone therapy and breast cancer risk. European Medicines Agency
- Hodis HN, Mack WJ. (2013). The Timing Hypothesis and Hormone Replacement Therapy: A Paradigm Shift in the Primary Prevention of Coronary Heart Disease in Women (Part 1 & Part 2). Journal of the American Geriatrics Society
- National Institute for Health and Care Excellence. (2024). NICE Guideline NG23: Menopause — diagnosis and management (current as of 2026). NICE
- Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC). (2019). Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. The Lancet. https://doi.org/10.1016/S0140-6736(19)31709-X

_Full guide: https://longevity-germany.com/en/guide/hormonersatztherapie-hrt-trt_

---

_Canonical: https://longevity-germany.com/en/guide/hormonersatztherapie-hrt-trt · Part of Longevity Cities · Updated 2026-06-22_